Product Description
Mechanisms of Action: 5-HT1A Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Alzheimer Disease
Phase 1: Alzheimer Disease|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
3098B1-1142 | P1 |
Completed |
Alzheimer Disease |
2008-09-01 |
|
2005-001478-28 | P2 |
Completed |
Alzheimer Disease |
2008-06-11 |
|
3098B1-203, 3098B1-204 | P3 |
Completed |
Alzheimer Disease |
2008-06-01 |
36% |
3098B1-201, 3098B1-202 | P2 |
Completed |
Alzheimer Disease |
2008-03-15 |
32% |